- The revenue growth came in higher than the industry average of 6.2%. Since the same quarter one year prior, revenues rose by 19.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
- UTHR's debt-to-equity ratio is very low at 0.29 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, UTHR has a quick ratio of 1.84, which demonstrates the ability of the company to cover short-term liquidity needs.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market, UNITED THERAPEUTICS CORP's return on equity exceeds that of both the industry average and the S&P 500.
- The gross profit margin for UNITED THERAPEUTICS CORP is currently very high, coming in at 91.20%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 41.80% significantly outperformed against the industry average.
NEW YORK ( TheStreet) -- United Therapeutics Corporation (Nasdaq: UTHR) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Highlights from the ratings report include: